Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROXYCHLOROQUINE SULFATE

All products: general benefit

Other products in the same Health Canada class (P01B) — coverage varies; not interchangeable

  • Atovaquone + proguanil (Malarone): not a benefit
  • Mefloquine (Lariam): not a benefit

Plaquenil · DIN 02017709 · 200mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists PLAQUENIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plaquenil · DIN 02017709 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2007-09-26 · brand PLAQUENIL · ATC P01BA02 HYDROXYCHLOROQUINE · form Tablet · route Oral · ingredients HYDROXYCHLOROQUINE SULFATE 200 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1576 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735 · Verify on the e-Formulary ↗ (DIN 02017709)

Source record
DIN 02017709: Plaquenil Raw flags: sec3=Y Item: 082000002; group id 120; item number 0203; lccId None; manufacturer id SAV Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.6786; ministry $0.1576 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02017709 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735
Interchangeable products
Apo-Hydroxyquine · DIN 02246691 · $0.1576 Hydroxychloroquine · DIN 02519348 · $0.1576 Jamp-Hydroxychloroquine · DIN 02491427 · $0.1576 Mint-Hydroxychloroquine · DIN 02424991 · $0.1576 NRA-Hydroxychloroquine · DIN 02511886 · $0.1576
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:20 Plasmodicides (Antimalarials)) and how they are covered

Matched class: 08:20 Plasmodicides (Antimalarials)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 08:20 Plasmodicides (Antimalarials)

ATOVAQUONE & PROGUANIL HCL

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg & 100mg · Tab

MEFLOQUINE HCL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:20
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications PLAQUENIL (hydroxychloroquine sulfate tablets) is indicated for: • the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, in adult patients who have not responded satisfactorily to drugs with less potential for serious side effects. • the suppressive treatment and treatment of acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. PLAQUENIL is not active against the exo-erythrocytic forms of P. vivax, P. malariae and P. ovale, and therefore will neither prevent infection due to these organisms when given prophylactically, nor prevent relapse of infection due to these organisms. PLAQUENIL is highly effective as a suppressive agent in patients with vivax or malariae malaria in terminating acute attacks and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria, PLAQUENIL abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum (see 7 Warnings and Precautions, General, Malaria). 1.1. Pediatrics Pediatrics (< 18 y… https://pdf.hres.ca/dpd_pm/00083189.PDF PM date: 2026-01-16 Source product: PLAQUENIL; DIN 02017709; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.